Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1152 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Ramucirumab in addition to erlotinib for EGFR mutation-positive metastatic non-small-cell lung cancer	Erlotinib (Tarceva; erlotinib hydrochloride) , Ramucirumab (Cyramza)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Ranibizumab Biosimilar for Age-related Macular Degeneration	Ranibizumab biosimilar (FYB201; BI695511; PF582; QL1205; Xlucane; SB11)	Age-related macular degeneration (AMD)	Ophthalmology	2021	View \| Download
Ranibizumab for proliferative and non-proliferative diabetic retinopathy	Ranibizumab (Lucentis Port Delivery System; Lucentis)	Diabetic retinopathy	Endocrine Nutritional and Metabolic Disorders , Ophthalmology	2018	View \| Download
Ranibizumab for Retinopathy of Prematurity – first line	Ranibizumab (Lucentis Port Delivery System; Lucentis)	Retinopathy of prematurity	Gynaecology and Obstetrics , Ophthalmology	2018	View \| Download
Ranibizumab port delivery system for the treatment of age-related macular degeneration	Ranibizumab (Lucentis Port Delivery System; Lucentis)	Age-related macular degeneration (AMD)	Ophthalmology	2020	View \| Download
Ranibizumab port delivery system for treating diabetic macular oedema	Ranibizumab (Lucentis Port Delivery System; Lucentis)	Diabetic macular oedema	Endocrine Nutritional and Metabolic Disorders , Ophthalmology	2022	View \| Download
Ravulizumab (subcutaneous formulation) for treating paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome	Ravulizumab (ALXN1210; Ultomiris)	Atypical haemolytic uraemic syndrome (aHUS) , Paroxysmal nocturnal haemoglobinuria (PNH)	Haematology , Nephrology	2022	View \| Download
Ravulizumab for atypical haemolytic uraemic syndrome in adults and children – first line	Ravulizumab (ALXN1210; Ultomiris)	Atypical haemolytic uraemic syndrome (aHUS)	Haematology , Nephrology	2018	View \| Download
Ravulizumab for paroxysmal nocturnal haemoglobinuria in paediatrics	Ravulizumab (ALXN1210; Ultomiris)	Paroxysmal nocturnal haemoglobinuria (PNH)	Haematology	2021	View \| Download
Ravulizumab for treating generalised myasthenia gravis	Ravulizumab (ALXN1210; Ultomiris)	Myasthenia gravis (MG)	Musculoskeletal System	2021	View \| Download